01—Abstract
Summary
Summary of the 10-K filed March 31, 2003. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals' FY2002 10-K (filed March 31, 2003) shows a company still in the pre-revenue, heavy-investment phase of its life cycle.
Total revenue was flat at about $22.0 milliona in both 2002 and 2001, while operating expenses rose 34% to $143.9 million, driven mainly by R&D of $124.9 million (up from $91.5 million) for the AXOKINE Phase III obesity program, the IL-1 Trap Phase II rheumatoid arthritis trial, and the Velocigene platform. The net loss widened to $124.4 million, or $2.83 per share, from $76.2 million, and the accumulated deficit reached $424.1 million. Cash, equivalents and marketable securities declined to $295.2 million from $438.4 million, and management says existing capital should fund operations only through mid-2004, so further financing or partnering is likely.
The most significant event disclosed is the March 31, 2003 release of preliminary Phase III AXOKINE data. AXOKINE produced statistically significant weight loss versus placebo (6.2 lbs vs. 2.6 lbs on an intent-to-treat basis), but the absolute effect is small, and the drug was limited by antibody development after about three months. Patients who did not develop antibodies lost substantially more weight (12.6 lbs vs. 4.5 lbs for placebo), and that subgroup is the basis of the company's case.
The filing also reports that the IL-1 Trap was partnered with Novartis on March 28, 2003. Novartis is providing $48.0 millionb in equity, a $27.0 million up-front payment, and up to $275.0 million in milestones, with profits shared equally in North America and Europe. This gives Regeneron meaningful non-dilutive funding and external validation for its cytokine-trap franchise.
For investors, the key issues are execution risk, the dependence on a single lead obesity candidate with a modest efficacy profile, the injectable-only delivery that competes with oral obesity drugs, and near-term financing needs. The IL-1 Trap rheumatoid arthritis Phase II readout expected mid-2003 and the completion of the AXOKINE diabetes and short-term studies are the near-term catalysts to watch.
02—Key points
Key Highlights
- Net loss widened to $124.4 million ($2.83 per share) in 2002 from $76.2 million ($1.81 per share) in 2001, driven by R&D spending of $124.9 million.
- Total revenue was essentially flat at $22.0 million, consisting mainly of Procter & Gamble research funding ($10.9M contract R&D) and Merck contract manufacturing ($11.1M); the company has no product sales.
- Preliminary Phase III AXOKINE obesity results (March 31, 2003) met both primary endpoints statistically, with 6.2 lbs average weight loss vs. 2.6 lbs for placebo, but the effect was modest and limited by antibody formation.
- Novartis collaboration on IL-1 Trap (March 2003) brings $27.0M up-front, a $48.0M equity purchase, up to $275.0M in milestones, and shared profits in North America and Europe.
- Cash, cash equivalents and marketable securities fell to $295.2 million from $438.4 million, and management expects existing capital to last only through mid-2004, signaling near-term financing needs.
- Accumulated deficit reached $424.1 million, and the company has no approved products or sales, so commercialization remains several years away.
- Near-term catalysts include the IL-1 Trap Phase II rheumatoid arthritis results expected mid-2003 and additional AXOKINE diabetes and short-term treatment studies.
03—Questions
Frequently Asked Questions
Has Regeneron generated any product revenue, and when might it?
No. Regeneron has not generated sales or profits from commercializing any product candidates. Its revenue comes from collaboration research funding (mainly Procter & Gamble) and contract manufacturing for Merck. Management says it does not expect commercial revenue for several years, and the approval path depends on clinical success and FDA review.
How significant is the AXOKINE Phase III result for obesity?
The results met statistical significance on the primary endpoints, but the average weight loss was small (6.2 lbs vs. 2.6 lbs for placebo over 12 months). Antibodies developed after about three months and limited efficacy for many patients. Patients who did not develop antibodies lost considerably more weight (12.6 lbs vs. 4.5 lbs), but that subgroup is only part of the population. AXOKINE is also injectable, while competing obesity drugs are oral, which may limit market acceptance.
Why is the Novartis deal important for Regeneron's financial position?
The Novartis agreement provides $27.0 million up front, a $48.0 million equity investment, and cost-sharing on IL-1 Trap development, with loans that may be forgiven if milestones are met. Regeneron may receive up to $275.0 million in milestones and shares profits in North America and Europe. This reduces the company's funding burden and provides external validation, although Novartis can terminate the agreement on specified notice.
How long will the company's cash last, and will it need more financing?
Management believes existing capital resources will fund operations through mid-2004, based on the current operating plan. Cash and securities fell to $295.2 million at year-end 2002 from $438.4 million, and net cash used in operations was $110.5 million in 2002. The company has no bank credit line and may need to raise funds through collaborations, public or private financings, or additional equity, which could dilute shareholders.
What are the main risks to investors?
Key risks include clinical trial failure or delay for AXOKINE and the IL-1 Trap, neutralizing antibody formation with recombinant proteins, the lack of approved products, dependence on collaborators such as Procter & Gamble and Merck, reliance on patents with some third-party blocking patents identified, competition from better-established therapies, and the need for additional financing. The company has a $200 million convertible note due 2008 with a conversion price of about $30.25, well above the $19.29 closing price in March 2003.
04—Continue